Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 SEP 21 ... (VEGF) represents a key mediator of tumor-initiated angiogenesis and the first target of antiangiogenesis agents introduced in clinical practice. VEGF and VEGF receptor antagonists have ...
2009 JUN 22 ... cytotoxic and that when injected locally in tumor tissue they might be effective antiangiogenesis agents suitable for cancer therapy. (Blood. 2009; 113:4197-4205)'."
...
2009 AUG 17 ... other diseases of the eye, radiotherapy combined with pharmaceutical agents, including antiangiogenesis therapies, have the potential to an additive or synergistic effect," wrote S.M. Hahn ...
2009 SEP 21 ... with elevation of apoptotic cell death, antiproliferation (inhibition of PCNA) and antiangiogenesis (inhibition of microvessel density). The in vitro study demonstrated that ...
2009 OCT 5 ... of OPN on HUVECs. In addition, blood vessel formation is also investigated in vivo. The antiangiogenesis efficacy of anti-OPN antibody in vivo is more effective than that of anti-VEGF antibody, ...
2009 NOV 9 ... concluded: "Biomarker evidence of antiangiogenic activity and DCE-MRI evidence of tumor antiangiogenesis were observed together with promising clinical activity." Wong and ...
2009 SEP 14 ... concluded: "Inhibition of S6K1 signaling downstream of mTOR is a major component of the antiangiogenesis action of rapamycin. (Arterioscler Thromb Vasc Biol. 2009; 29:1172-1178.)." ...
2009 SEP 28 ... glucuronide (9ACG), and elucidating the synergistically antitumor effects of antiangiogenesis therapy by targeting the tumor microenvironment. We analyzed the antitumor effects of ...
2009 SEP 7 ... the tumor tissues and blood samples were collected to analyze the kinetics of antitumor, antiangiogenesis, and antivascularization responses of different therapies. In human nasopharyngeal ...
2009 OCT 12 ... (VEGF) levels compared with untreated metastatic groups. MK is a key antimetastatic and antiangiogenesis compound in RMRE, as shown by down-regulation of VEGF-stimulated invasive activity in ...
2009 AUG 17 ... "Radiotherapy is a promising adjunctive tool to antiangiogenesis therapies for control of the choroidal neovascularization that characterizes exudative ...
2009 SEP 28 ... inhibitor, and may provide a better tool for studying tumor angiogenesis and antiangiogenesis drugs in HCC." Xiong and colleagues published their study in Clinical ...
2009 JUL 20 ... of cell proliferation in the tumors by P61A6 treatment, but neither apoptosis nor antiangiogenesis was observed. Increased cytosolic localization of proteins such as Rap 1 and RhoA in ...
2009 OCT 19 ... The researchers concluded: "The extent of tumor necrosis suggested an antiangiogenesis-dependent inhibition of tumor development." Margheri and colleagues ...
2009 SEP 7 ... conducted to examine apoptosis, microvessel density and histological morphology changes. Antiangiogenesis was determined by the alginate-encapsulated tumor cell assay. The recombinant PEDF ...
2009 SEP 14 ... and tube formation of ECV-304 cells were determined by MTT and matrigel assays. The antiangiogenesis effect of celastrol was assessed by the chick chorioallantoic membrane assay and the in ...
2009 OCT 12 ... found in patients. Targeting of tumor vasculature by Lipoplatin in animals suggested its antiangiogenesis potential and Lipoplatin was proposed to act like a double-sword: as chemotherapy and an ...
2009 JUL 27 ... angiogenesis was a crucial step in the development of tumor, thus the immunotherapy of antiangiogenesis has been involved as potentially relevant candidate targets of cancer immunotherapy. ...
2009 AUG 17 ... inhibited the growth of PC-9/VanR tumors in an in vivo xenograft model through the antiangiogenesis effects of VEGFR-2 inhibition," wrote E. Ichihara and colleagues, Okayama University. ...
2009 AUG 17 ... "Photodynamic therapy has been widely replaced by antiangiogenesis agents for the first-line therapy for exudative age-related macular degeneration (AMD). ...
